Rule 3.8A

## Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name	of entity	ABN/ARSN	
Sign	na Pharmaceuticals Limited	15 088 417 403	
We (	the entity) give ASX the following	information.	
Info	ormation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASX	13 September 2012 (Associated Appendix 2014)	3D dated 2 October
	al of all shares/units bought e been received, before, and	on, previous day	_
	9	-	o which acceptances  Previous day
	9	on, previous day	_

		Before previous day			Previous day
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.7850
		Lowest \$0.5600	price	paid:	Lowest price paid: \$0.7800 Highest price allowed under rule 7.33: \$0.8477

## How many shares/units may still be bought back?

6	If the company/trust has disclosed	15,589,777
	an intention to buy back a	
	maximum number of shares/units	
	- the remaining number of	
	shares/units to be bought back	
	•	

## **Compliance statement**

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 17 June 2015

(Director/Company secretary)

Print name: SUE MORGAN

== == == == ==